drugset / Trial / NCT03533816
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
Non-randomizedSequentialOpen-labelTreatment
Summary
Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in leukemic and myelodysplastic patients who have had a partially mismatched bone marrow transplant (haploidentical).
Timeline
- Start
- 2020-01-31
- Primary completion
- 2027-01
- Completion
- 2028-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EAGD T-cell infusion | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | EAGD T-cell infusion | Cell therapy | 3e+06 cells/kg | Intravenous |
| Subject | EAGD T-cell infusion | Cell therapy | 1e+07 cells/kg | Intravenous |